CClinicalTrials.gg
Active, not recruitingNCT06119464Updated May 27, 2026

Re-Purposing the Ordering of 'Routine' Laboratory Tests in Hospitalized Medical Patients (RePORT Study)

An interventional study of Multimodal Intervention: Education and Multimodal Intervention: Audit and Feedback in Utilization, Health Care, sponsored by University of Calgary. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by University of Calgary · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2023, registered Oct 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
251,817
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Laboratory test overuse occurs when tests are ordered repetitively, without due consideration of impact on clinical status. Repetitive inpatient lab testing often provides limited value for patient outcomes while increasing healthcare costs, patient discomfort, and unnecessary transfusions and prolonging hospitalizations. The research study aims to reduce laboratory test overuse in hospitals through implementation of a comprehensive, multi-disciplinary, and multi-faceted intervention bundle that includes audit and feedback reports, clinician education, clinical decision support tool, and patient infographics across 14 hospitals in Alberta.

Read the detailed description

Background: Laboratory and Pathology testing contributes to rising health care expenditure. A relatively large percentage (up to 42%) of laboratory testing can be considered wasteful. Redundant testing alone has been estimated to waste up to 5 billion dollars annually in the United States of America. Laboratory over-utilization leads to false positives that promotes further inappropriate testing and procedures, interruption of normal sleep pattern of inpatients, as well as iatrogenic anemia and pain. A Canadian study showed significant hemoglobin reductions as a result of phlebotomy. Studies support the safe reduction of repetitive laboratory testing without negative effects on adverse events, readmission rates, critical care utilization, or mortality.

The aim of this research study is the following:

  1. To implement a multimodal intervention bundle containing healthcare provider and patient engagement tools for hospitalized medical inpatients in 14 hospitals across the province of Alberta in Canada using a cluster randomized stepped-wedge design
  2. To evaluate the impact of the intervention bundle on laboratory test utilization of six target laboratory tests (complete blood count, electrolytes, creatinine, urea, partial thromboplastin time, and international normalized ratio), costs, and patient safety outcomes.

This intervention bundle will be implemented across all the adult hospital sites in Alberta starting January 2023 and evaluated until October 2024.

02

Conditions studied

  • Utilization, Health Care

Keywords

  • Overutilization of lab test
  • Multimodal intervention
  • Lab test overuse
  • Laboratory
  • Hospital
03

In context

Patient Acceptance of Health Care

93 studies on the registry are indexed under Patient Acceptance of Health Care; 30 are open to participants now.

This study's planned enrollment of 251,817 is above the median of 238 across 74 interventional studies indexed under Patient Acceptance of Health Care.

Browse Patient Acceptance of Health Care studies →

Lead sponsor

University of Calgary is the lead sponsor of 686 studies on the registry; 189 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • all participants (patients and healthcare providers) within enrolled adult hospitals in Alberta of medical and hospitalist units during study period

Exclusion criteria

Exclusion Criteria:

  • outside of the above-mentioned province
  • hospitals not enrolled
  • non-medical units (eg. ICU, surgical, pediatric, obstetrical units)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
251,817 participants (estimated)

Study arms

  • No intervention
    Unexposed to intervention (control period)

    This is the time period of the study where hospital clusters are not receiving the intervention

  • Experimental
    Exposed to intervention (intervention period)

    This is the time period of the study where hospital clusters are receiving the multimodal intervention.

    Other: Multimodal Intervention: Education · Other: Multimodal Intervention: Audit and Feedback · Other: Multimodal Intervention: Patient Engagement · Other: Multimodal Intervention: System Changes

Interventions

  • OtherMultimodal Intervention: Education

    The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

  • OtherMultimodal Intervention: Audit and Feedback

    The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

  • OtherMultimodal Intervention: Patient Engagement

    The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

  • OtherMultimodal Intervention: System Changes

    The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

06

What researchers measure

Primary outcomes

  1. Number of routine laboratory tests ordered per patient-day in the intervention versus control periods

    Number of the six target laboratory tests (complete blood count, electrolytes, creatinine, urea, international normalized ratio and partial thromboplastin time) ordered per patient-day

    Time frame: 1 year 9 months

Secondary outcomes

  1. Costs associated with routine and all common laboratory test ordered

    Costs of test and associated costs with and without intervention

    Time frame: 1 year 9 months

  2. Proportion of hospital patient lab-free days

    Number of hospital patient-days not associated with laboratory blood draws

    Time frame: 1 year 9 months

  3. Proportion of critically abnormal test results

    As defined by lab standards, we will track the proportion of critically abnormal test results

    Time frame: 1 year 9 months

  4. Length of stay

    Patient length of stay on the unit

    Time frame: 1 year 9 months

  5. Transfer to Intensive Care Unit

    Transfer rate to Intensive Care Unit

    Time frame: 1 year 9 months

  6. In-patient and 30-day patient mortality over study period

    Mortality rate in hospital and at 30-days post discharge

    Time frame: 30 days post discharge

  7. 30-day post discharge readmission rate

    Hospital re-admission within 30 days post discharge

    Time frame: 30 days post discharge

  8. Number of all common laboratory tests

    Number of all common laboratory tests (tests that contribute to \>80% of hospital laboratory test utilization during study period) per patient-day.

    Time frame: 1 year 9 months

07

Study locations

1 site
  • University of Calgary
    Calgary, Alberta T2N 1N4, Canada
08

References and documents

Individual participant data

Plan to share: No — Study data and results will be available for sharing with other researchers who follow the ethical and institutional protocols required by hospitals and health systems involved to obtain the same data

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06119464
Lead sponsor
University of Calgary
Collaborators
Alberta Health services, University of British Columbia, Canadian Institutes of Health Research (CIHR)
Responsible party
Anshula Ambasta (Clinical Assistant Professor, University of Calgary) — Principal investigator
First posted
Nov 7, 2023
Start date
Jan 2, 2023
Primary completion
Oct 31, 2024
Completion
Oct 2026 (estimated)
Last update
May 27, 2026

Study contacts

Anshula Ambasta
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion